litlas
Log inCreate account

Stéphane Dalle

Active 1999–2026

Also published as
Stephane Dalle
158
Papers
22,119
Citations
74
h-index
145
i10-index

Citations

Citations per year for Stéphane Dalle2000: 1 citations2001: 8 citations2002: 12 citations2003: 26 citations2004: 25 citations2005: 20 citations2006: 27 citations2007: 24 citations2008: 25 citations2009: 36 citations2010: 44 citations2011: 61 citations2012: 49 citations2013: 83 citations2014: 74 citations2015: 70 citations2016: 52 citations2017: 70 citations2018: 165 citations2019: 792 citations2020: 1,038 citations2021: 1,076 citations2022: 1,082 citations2023: 1,010 citations2024: 1,527 citations2025: 782 citations2026: 20 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,557 citing papers, 23.8% of this breakdownChina: 1,097 citing papers, 10.2% of this breakdownItaly: 713 citing papers, 6.7% of this breakdownFrance: 645 citing papers, 6% of this breakdownGermany: 616 citing papers, 5.7% of this breakdownUnited Kingdom: 608 citing papers, 5.7% of this breakdownAustralia: 470 citing papers, 4.4% of this breakdownNetherlands: 342 citing papers, 3.2% of this breakdownSpain: 338 citing papers, 3.2% of this breakdownCanada: 323 citing papers, 3% of this breakdownJapan: 315 citing papers, 2.9% of this breakdownSwitzerland: 312 citing papers, 2.9% of this breakdown
0%23.8%Other 22.3%

Institutions

Fields

  • Medicine70.2%
  • Biochemistry, Genetics and Molecular Biology18.1%
  • Immunology and Microbiology5.9%
  • Neuroscience3.6%
  • Engineering0.6%
  • Pharmacology, Toxicology and Pharmaceutics0.3%
  • Other1.3%

Topics

  • Cancer Immunotherapy and Biomarkers14.2%
  • CAR-T cell therapy research5.6%
  • Immunotherapy and Immune Responses5%
  • Cutaneous Melanoma Detection and Management4.6%
  • Melanoma and MAPK Pathways3.7%
  • Immune Cell Function and Interaction2.5%
  • Other64.4%

Coauthors

All papers

Open in search
  1. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

    Authors: Hussein A. Tawbi, Dirk Schadendorf, Evan J. Lipson, Paolo A. Ascierto, Luis Matamala, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen J. Gogas, Christopher D. Lao, Juliana Janoski De Menezes, Stéphane Dalle, Ana Arance, Jean-Jacques Grob, Shivani Srivastava, Mena Abaskharoun, Melissa Hamilton, Sarah Keidel, Katy L. Simonsen, Anne Marie Sobiesk, Bin Li, F. Stephen Hodi, Georgina V. Long - New England Journal of Medicine 2022 cited by 1,759

  2. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

    Authors: Georgina V. Long, Reinhard Dummer, Omid Hamid, Thomas F. Gajewski, Christian Caglevic, Stéphane Dalle, Ana Arance, Matteo S. Carlino, Jean‐Jacques Grob, Tae Min Kim, Lev Demidov, Caroline Robert, James Larkin, James R. Anderson, Janet Maleski, Mark M. Jones, Scott J. Diede, Tara C. Mitchell - The Lancet Oncology 2019 cited by 944

  3. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

    Authors: Jeffrey S. Weber, Mario Mandalà, Michele Del Vecchio, Helen Gogas, Ana Arance, C. Lance Cowey, Stéphane Dalle, Michael Schenker, Vanna Chiarion‐Sileni, Iván Márquez‐Rodas, Jean-Jacques Grob, Marcus O. Butler, Mark R. Middleton, Michele Maio, Victoria Atkinson, Paola Queirolo, René González, Ragini R. Kudchadkar, Michael Smylie, Nicolás Meyer, Laurent Mortier, Michael B. Atkins, Georgina V. Long, Shailender Bhatia, Célèste Lebbé, Piotr Rutkowski, Kenji Yokota, Naoya Yamazaki, Tae M. Kim, Veerle de Pril, Javier Sabater, Anila Qureshi, James Larkin, Paolo A. Ascierto - New England Journal of Medicine 2017 cited by 2,207

  4. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

    Authors: Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Mikhail Lichinitser, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Michele Maio, Alfonsus Johannes Maria van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Nageatte Ibrahim, Sandrine Marréaud, Alexander C. J. van Akkooi, Stefan Suciu, Caroline Robert - New England Journal of Medicine 2018 cited by 1,853

  5. Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

    Authors: Paolo A. Ascierto, Michele Del Vecchio, Mario Mandalà, Helen Gogas, Ana Arance, Stéphane Dalle, C. Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion‐Sileni, Iván Márquez‐Rodas, Marcus O. Butler, Michele Maio, Mark R. Middleton, Luis de la Cruz‐Merino, Petr Arenberger, Victoria Atkinson, Andrew Hill, Leslie A. Fecher, Michael Millward, Nikhil I. Khushalani, Paola Queirolo, Maurice Lobo, Veerle de Pril, John T. Loffredo, James Larkin, Jeffrey S. Weber - The Lancet Oncology 2020 cited by 525

  6. Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial

    Authors: Paolo A. Ascierto, Evan J. Lipson, Reinhard Dummer, James Larkin, Georgina V. Long, Rachel E. Sanborn, Vanna Chiarion‐Sileni, Brigitte Dréno, Stéphane Dalle, Dirk Schadendorf, Margaret K. Callahan, Marta Nyakas, Victoria Atkinson, Carlos Gomez‐Roca, Naoya Yamazaki, Hussein A. Tawbi, Naomey Sarkis, Deepti Warad, Sonia Dolfi, Priyam Mitra, Satyendra Suryawanshi, Jean‐Jacques Grob - Journal of Clinical Oncology 2023 cited by 155

  7. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

    Authors: James Larkin, Michele Del Vecchio, Mario Mandalà, Helen Gogas, Ana Arance, Stéphane Dalle, Charles Lance Cowey, Michael Schenker, Jean‐Jacques Grob, Vanna Chiarion‐Sileni, Iván Márquez‐Rodas, Marcus O. Butler, Anna Maria Di Giacomo, Mark R. Middleton, Jose Lutzky, Luis de la Cruz‐Merino, Petr Arenberger, Victoria Atkinson, Andrew G. Hill, Leslie A. Fecher, Michael Millward, Paul Nathan, Nikhil I. Khushalani, Paola Queirolo, Corey Ritchings, Maurice Lobo, Margarita Askelson, Hao Tang, Sonia Dolfi, Paolo A. Ascierto, Jeffrey S. Weber - Clinical Cancer Research 2023 cited by 180

  8. Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma

    Authors: Georgina V. Long, F. Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala, Pamela Salman, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, J. Menezes, Stéphane Dalle, Ana Arance, Jean‐Jacques Grob, Sarah Keidel, Anadil Shaikh, Anne Marie Sobiesk, Sonia Dolfi, Hussein A. Tawbi - NEJM Evidence 2023 cited by 124

  9. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

    Authors: Alexander Eggermont, Christian U. Blank, Mario Mandalà, Georgina V Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Anna Maria Di Giacomo, Alfons J.M. van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Alexander C. J. van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marréaud, Michal Kiciński, Stefan Suciu, Caroline Robert, Alex Menzies, Thierry Lesimple, Michele Maio, Gerald P. Linette, Michael P. Brown, Peter Hersey, Inge Marie Svane, Laurent Mortier, Jacob Schachter, Catherine Barrow, Ragini R. Kudchadkar, Xinni Song, Caroline Dutriaux, Pietro Quaglino, Friedegund Meier, Paola Queirolo, Daniil Stroyakovskiy, Lars Bastholt, B. Guillot, Claus Garbe, Pablo L. Ortiz‐Romero, Florent Grange, Peter Mohr, Alain P. Algazi, Oliver Bechter, Micaela Hernberg, Jean‐Philippe Arnault, Philippe Saïag, Carmen Loquai, Frank Meiß, Jan‐Christoph Simon, Gil Bar‐Sela, Vanna Chiarion‐Sileni, Bernard M. Fitzharris, Mike McCrystal, Phillip Parente, Jean‐François Baurain, P. Combemale, Célèste Lebbé, Axel Hauschild, Naoya Yamazaki, Reinhard Dummer, Mohammed Milhem, Marcin Dzienis, John Walker, L. Geoffrois, M.‐T. Leccia, Lutz Kretschmer, Daniel Hendler, Michal Lotem, Andrzej Maćkiewicz, Lidija Kandolf Sekulović, Elaine Dunwoodie, Christoph Höeller, L. Machet, Jessica C. Hassel, Geke A.P. Hospers, Maria-Jose Passos, Max Levin, Martin Fehr, Philippa Corrie, Ashita Waterston, Sigrun Hallmeyer, Henrik Schmidt, V. Descamps, J.‐P. Lacour, Carola Berking, Felix Kiecker, Pier Francesco Ferrucci and 32 more - The Lancet Oncology 2021 cited by 389

  10. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

    Authors: Youn H. Kim, M. Bagot, Lauren Pinter‐Brown, Alain H. Rook, Pierluigi Porcu, Sarah McCue Horwitz, Sean Whittaker, Y. Tokura, Maarten H. Vermeer, Pier Luigi Zinzani, Lubomir Sokol, Stephen Morris, Ellen J. Kim, Pablo L. Ortiz‐Romero, Herbert Eradat, Julia Scarisbrick, Athanasios Tsianakas, Craig A. Elmets, Stéphane Dalle, David C. Fisher, Ahmad Halwani, Brian Poligone, John P. Greer, Maria Teresa Fierro, Amit Khot, Alison J. Moskowitz, Amy Musiek, Andrei R. Shustov, Barbara Pro, Larisa J. Geskin, Karen M. Dwyer, Junji Moriya, Mollie Leoni, Jeffrey S. Humphrey, Stacie Hudgens, Dmitri O. Grebennik, Kensei Tobinai, Madeleine Duvic, Sunil Abhyankar, Oleg E. Akilov, Önder Alpdoğan, M. Beylot‐Barry, Erin Boh, Dolores Caballero, Richard Cowan, Brigitte Dréno, Reinhard Dummer, Timothy S. Fenske, Francine Foss, Noriko Fukuhara, Pratyush Giri, Koji Habe, Toshihisa Hamada, Kiyohiko Hatake, Shinsuke Iida, Osamu Ishikawa, Lars Iversen, Eiji Kiyohara, Hiroshi Koga, Neil J. Korman, Bryone J. Kuss, Zanetta S. Lamar, Frederick Lansigan, Mary Jo Lechowicz, Adam Lerner, Nina Magnolo, Lawrence A. Mark, Tomomitsu Miyagaki, Javier Muñoz, Jan P. Nicolay, Kaoru Nishiwaki, Hiroyuki Okamoto, Mikio Ohtsuka, Theresa Pacheco, Christiane Querfeld, Ronald Peter Rapini, Shigetoshi Sano, Maiko Tanaka, Michael D. Tharp, Jiro Uehara, Hidefumi Wada, Jillian Wells, Ryan A. Wilcox, Basem M. William, Kentaro Yonekura - The Lancet Oncology 2018 cited by 645

  11. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo

    Authors: Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Anna Maria Di Giacomo, Alfonsus Johannes Maria van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Clemens Krepler, Nageatte Ibrahim, Sandrine Marréaud, Alexander C. J. van Akkooi, Caroline Robert, Stefan Suciu - JAMA Oncology 2020 cited by 436

  12. Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma

    Authors: Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Marye J. Boers‐Sonderen, Anna Maria Di Giacomo, Alfonsus Johannes Maria van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C. J. van Akkooi, Paul Lorigan, Dmitri Grebennik, Clemens Krepler, Sandrine Marréaud, Stefan Suciu, Caroline Robert - NEJM Evidence 2022 cited by 150

  13. Regulatory T cells promote cancer immune-escape through integrin αvβ8-mediated TGF-β activation

    Authors: Alexandra Lainé, Ossama Labiad, Héctor Hernández‐Vargas, Sébastien This, Amélien Sanlaville, Sophie Léon, Stéphane Dalle, Dean Sheppard, Mark A. Travis, Helena Païdassi, Julien C. Marie - Nature Communications 2021 cited by 165

  14. Adipocyte extracellular vesicles carry enzymes and fatty acids that stimulate mitochondrial metabolism and remodeling in tumor cells

    Authors: Emily Clement, Ikrame Lazar, Camille Attané, Lorry Carrié, Stéphanie Dauvillier, Manuelle Ducoux‐Petit, David Estève, Thomas Menneteau, Mohamed Moutahir, Sophie Le Gonidec, Stéphane Dalle, Philippe Valet, Odile Burlet‐Schiltz, Catherine Muller, Laurence Nieto - The EMBO Journal 2020 cited by 236

  15. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial

    Authors: Alexander Stratigos, Aleksandar Sekulić, Ketty Peris, Oliver Bechter, S. Prey, Martin Kaatz, Karl D. Lewis, Nicole Basset‐Séguin, Anne Lynn S. Chang, Stéphane Dalle, Almudena Fernández Orland, Lisa Licitra, Caroline Robert, Claas Ulrich, Axel Hauschild, Michael R. Migden, Reinhard Dummer, Siyu Li, Suk-Young Yoo, Kosalai Kal Mohan, Ebony Coates, Vladimir Janković, Nathalie Fiaschi, Emmanuel Chiebuka Okoye, Ioannis D. Bassukas, Carmen Loquai, Vincenzo De Giorgi, Zeynep Eroglu, Ralf Gutzmer, Jens Ulrich, Susana Puig, Frank Seebach, Gavin Thurston, David M. Weinreich, George D. Yancopoulos, Israel Lowy, Timothy G. Bowler, Matthew G. Fury - The Lancet Oncology 2021 cited by 278

  16. Adipocyte Exosomes Promote Melanoma Aggressiveness through Fatty Acid Oxidation: A Novel Mechanism Linking Obesity and Cancer

    Authors: Ikrame Lazar, Emily Clement, Stéphanie Dauvillier, Delphine Milhas, Manuelle Ducoux‐Petit, Sophie Le Gonidec, Cédric Moro, Vanessa Soldan, Stéphane Dalle, Stéphanie Balor, Muriel Golzio, Odile Burlet‐Schiltz, Philippe Valet, Catherine Muller, Laurence Nieto - Cancer Research 2016 cited by 397

  17. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

    Authors: Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Anna Maria Di Giacomo, Alfonsus Johannes Maria van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Alexander C. J. van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marréaud, Michal Kiciński, Stefan Suciu, Caroline Robert - Journal of Clinical Oncology 2020 cited by 281

  18. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

    Authors: Myriam Delaunay, J. Cadranel, Amélie Lusque, Nicolás Meyer, V. Gounant, Denis Moro‐Sibilot, Jean‐Marie Michot, Judith Raimbourg, Nicolas Girard, Florian Guisier, David Planchard, Anne-Cécile Métivier, Pascale Tomasini, Éric Dansin, M. Pérol, M. Campana, Oliver Gautschi, Martin Früh, Jean-David Fumet, Clarisse Audigier-Valette, S. Couraud, Stéphane Dalle, M.‐T. Leccia, M. Jaffro, S. Collot, Grégoire Prévôt, Julie Milia, Julien Mazières - European Respiratory Journal 2017 cited by 421

  19. Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

    Authors: Jeffrey S. Weber, Dirk Schadendorf, Michele Del Vecchio, James Larkin, Victoria Atkinson, Michael Schenker, Jacopo Pigozzo, Helen Gogas, Stéphane Dalle, Nicolás Meyer, Paolo A. Ascierto, Shahneen Sandhu, Thomas Eigentler, Ralf Gutzmer, Jessica C. Hassel, Caroline Robert, Matteo S. Carlino, Anna Maria Di Giacomo, Marcus O. Butler, Eva Muñoz‐Couselo, Michael P. Brown, Piotr Rutkowski, Andrew Haydon, Jean‐Jacques Grob, Jacob Schachter, Paola Queirolo, Luis de la Cruz‐Merino, André van der Westhuizen, Alexander M. Menzies, Sandra Re, Tuba Öcek Baş, Veerle de Pril, Julia Braverman, Daniel J. Tenney, Hao Tang, Georgina V. Long - Journal of Clinical Oncology 2022 cited by 162

  20. A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors

    Authors: Patrick Arnaud‐Coffin, Denis Maillet, Hui Gan, Jean‐Jacques Stelmes, Benoît You, Stéphane Dalle, Julien Péron - International Journal of Cancer 2019 cited by 253

  21. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

    Authors: H. Miles Prince, Youn H. Kim, Sarah McCue Horwitz, Reinhard Dummer, Julia Scarisbrick, Pietro Quaglino, Pier Luigi Zinzani, Pascal Wolter, José Antônio Sanches, Pablo L. Ortiz‐Romero, Oleg E. Akilov, Larisa J. Geskin, Judith Trotman, Kerry Taylor, Stéphane Dalle, Michael Weichenthal, Jan Walewski, David C. Fisher, Brigitte Dréno, Rudolf Stadler, Tatyana Feldman, Timothy M. Kuzel, Yinghui Wang, Maria Corinna Palanca-Wessels, Erin Zagadailov, William L. Trepicchio, Wenwen Zhang, Huimin Lin, Yi Liu, Dirk Huebner, Meredith Little, Sean Whittaker, Madeleine Duvic, Judith Trotman, David Joske, H. Miles Prince, Kerry Taylor, Ian D. Lewis, Constanze Jonak, Franz Trautinger, Oliver Bechter, Pascal Wolter, Dominique Bron, Vladmir Cláudio Cordeiro de Lima, José Antônio Sanches, Richard Klasa, M. Bagot, M. Beylot‐Barry, Stéphane Dalle, M. D’Incan, Brigitte Dréno, Florent Grange, Jan P. Nicolay, Rudolf Stadler, Michael Weichenthal, Marion Wobser, Chalid Assaf, Carmen Loquai, Pietro Quaglino, Michele Spina, Pier Luigi Zinzani, Alberto Bosi, Pier Paolo Fattori, Aleksandra Grzanka, Jan Walewski, Andrés López‐Hernandez, Pablo L. Ortiz‐Romero, José J. Rifón Roca, Silvana Novelli Canales, Reinhard Dummer, Tim Illidge, Rod Johnson, Sean Whittaker, Stephen Morris, Pam McKay, Julia Scarisbrick, Madeleine Duvic, Tatyana Feldman, Oleg E. Akilov, Larisa J. Geskin, Steve Horwitz, Youn H. Kim, Barbara Pro, Timothy M. Kuzel, Adam Lerner, Herbert Eradat, Lubomir Sokol, David C. Fisher, S. Morgan Hughey - The Lancet 2017 cited by 580

  22. Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort

    Authors: Lina Hountondji, Christophe Ferreira De Matos, Fanny Lebossé, Xavier Quantin, C. Lesage, Pascale Palassin, Valérian Rivet, Stéphanie Faure, Georges‐Philippe Pageaux, Eric Assénat, Laurent Alric, Amel Zahhaf, Dominique Larrey, Philine Witkowski Durand Viel, Benjamin Rivière, Janick Sèlves, Stéphane Dalle, A. Maria, Thibaut Comont, Lucy Meunier - JHEP Reports 2023 cited by 84

  23. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease

    Authors: François‐Xavier Danlos, Anne-Laure Voisin, Valérie Dyevre, Jean‐Marie Michot, Émilie Routier, Laurent Taillade, Stéphane Champiat, Sandrine Aspeslagh, Julien Haroche, Laurence Albigès, Christophe Massard, Nicolas Girard, Stéphane Dalle, Benjamin Besse, Salim Laghouati, Jean‐Charles Soria, Christine Mateus, Caroline Robert, Émilie Lanoy, Aurélien Marabelle, Olivier Lambotte - European Journal of Cancer 2018 cited by 311

  24. ZEB1 transcription factor promotes immune escape in melanoma

    Authors: Maud Plaschka, Valentin Benboubker, Maxime Grimont, Justine Berthet, Laurie Tonon, Jonathan Lopez, Myrtille Le-Bouar, B. Balme, G Tondeur, Arnaud de la Fouchardière, Lionel Larue, Alain Puisieux, Yenkel Grinberg‐Bleyer, Nathalie Bendriss‐Vermare, Bertrand Dubois, Christophe Caux, Stéphane Dalle, Julie Caramel - Journal for ImmunoTherapy of Cancer 2022 cited by 106